by William Kinney | Jul 19, 2016 | IteraMed News
Bill Kinney and Doug Brenneman are featured in Sports Illustrated article about the potential of cannabidiol (CBD) in traumatic head injury and a new improved “Super-CBD” or KLS-13019 that is 50 times more potent, >400 times safer, 10 times more orally...
by William Kinney | Feb 15, 2016 | IteraMed News
The research behind the identification of KLS-13019 as a Lead Candidate has been published in American Chemical Society’s ACS Medicinal Chemistry Letters. This novel cannabidiol-like compound has potential to treat neurodegenerative and oxidative stress related...
by IteraMed | Aug 12, 2015 | IteraMed News
Ascot, UK, Dr. Kinney will describe for the first time a new family of molecules with improvements over Cannabidiol (“CBD”), a non-psychoactive neuroprotective agent from C. sativa. IteraMed Consulting has functioned as Kannalife Sciences’ medicinal and...
by IteraMed | Apr 4, 2013 | IteraMed News
KannaLife Sciences, Inc. (“KannaLife”) announces its collaboration with two experienced drug discovery organizations: Advanced Neural Dynamics and IteraMed. KannaLife will fund a new drug discovery project related to a laboratory validated phytochemical. The founding...
